he comparison between the last 3 groups). NT-proBNP levels were 301.0 (103.8, 919.8) and 303.0 (115.8, 876.5) pg/ml in patients developing carcinoma and adenocarcinoma, respectively (p = 0.808). A univariate Cox regression analysis revealed that only age (hazard ratio [HR] = 1.036 [95% confidence interval (CI) = 1.002.072]; p = 0.039), and NT-proBNP (HR = 1.016 [CI = 1.0011.033] per 100 pg/ml increment; p = 0.041) and triglyceride (HR = 0.988 [CI = 0.978.999]; p = 0.032) plasma levels were associated with a new diagnosis of cancer. All other variables displayed in Table 1 did not reach statistical significance (not shown). By multivariate Cox regression analysis, only NT-proBNP (HR = 1.030 [CI = 1.008.053] per 100 pg/ml increase; p = 0.007) and triglyceride levels (HR = 0.987 [CI = 0.975.998]; p = 0.024) remained as independent predictors of a new diagnosis of cancer. There was no difference in the use of statins between both groups (Table 1). No patients in the cancer group were receiving fibrates, as compared to 6.1% in the group that had not developed cancer (p = 0.390). In four patients, the suspicion of cancer was raised during the first one hundred days of follow-up. These patients showed no significant differences in age, glomerular filtration rate, or NT-proBNP (121.3 [51.8, 700.3] vs 317.0 [175.3, 981.3] pg/ml; p = 0.157), triglyceride (81.5 [61.5, 95.5] vs 92.5 [72.5, 136.7] mg/dl; p = 0.273), glucose, LDL, HDL, non-HDL, high-sensitivity C-reactive protein, MCP-1, galectin-3, high-sensitivity cardiac troponin I, and sTWEAK plasma levels as compared to those presenting later. When Cox multivariate regression analysis was repeated excluding these four patients, NT-proBNP (HR 10205015 = 1.061 [CI = 1.034.088] per 100 pg/ml increase; p0.001) was the only variable showing independent predictive value for the appearance of new malignancies.
NT-proBNP levels were higher in women than in men (239.0 [130.5, 561.5] vs 156.0 [82.6, 359.0] pg/ml; p0.001), and in patients with hypertension (225.0 [114.0, 530.0] vs 111.5 [62.7, 223.0] pg/ml; p0.001) and with previous atrial fibrillation (886.0 [316.0, 1860.0] vs 162.0 [85.9, 378.0] pg/ml; p0.001) as compared with those not suffering these conditions. Linear regression analyses were performed to assess the extent to which NT-proBNP levels could be explained by other variables. Given that the distribution of all biomarkers was asymmetric, we used logarithms for this analysis. NT-proBNP showed significant but mild correlations with age, glomerular filtration rate, and with plasma levels of high-sensitivity C-reactive protein, high-sensitivity cardiac troponin I, MCP-1, galectin-3, and MK 8931 triglycerides, (Fig 3), indicating that these variables did not explain most of NT-proBNP variability. The correlation with bodymass index and sTWEAK was not significant (R2 = 0.002, p = 0.305; and R2 = 0.000, p = 0.856, respectively). By multivariate linear regression analysis all the variables exhibiting a significant relationship with NT-proBNP at univariate analysis were significant, with the exception of galectin-3 (Table 2). These variables explained about 41% of the variations of NT-proBNP.
In addition to 24 cancers, 19 patients developed heart failure, and 23 died, yielding a total of 66 events. However, some patients had two events: 9 presented heart failure and death and 6 had developed a new malignancy and death. So the 
total number of patients having at least one event was 51. The cause of death was heart failur
